ANL 32.50 Decreased By ▼ -0.30 (-0.91%)
ASC 14.38 Decreased By ▼ -0.22 (-1.51%)
ASL 22.65 Decreased By ▼ -0.24 (-1.05%)
AVN 86.95 Decreased By ▼ -0.93 (-1.06%)
BOP 7.92 Decreased By ▼ -0.05 (-0.63%)
BYCO 9.94 Decreased By ▼ -0.02 (-0.2%)
DGKC 116.00 Decreased By ▼ -0.20 (-0.17%)
EPCL 52.50 Decreased By ▼ -1.00 (-1.87%)
FCCL 23.25 Decreased By ▼ -0.43 (-1.82%)
FFBL 26.65 Decreased By ▼ -0.90 (-3.27%)
FFL 15.20 Decreased By ▼ -0.10 (-0.65%)
HASCOL 9.15 Decreased By ▼ -0.10 (-1.08%)
HUBC 75.50 Decreased By ▼ -1.00 (-1.31%)
HUMNL 6.15 Decreased By ▼ -0.04 (-0.65%)
JSCL 20.15 Decreased By ▼ -0.36 (-1.76%)
KAPCO 38.10 Decreased By ▼ -0.60 (-1.55%)
KEL 3.70 Decreased By ▼ -0.06 (-1.6%)
LOTCHEM 15.00 Decreased By ▼ -0.50 (-3.23%)
MLCF 42.99 Decreased By ▼ -0.76 (-1.74%)
PAEL 32.57 Decreased By ▼ -0.13 (-0.4%)
PIBTL 10.00 Increased By ▲ 0.05 (0.5%)
POWER 8.79 Increased By ▲ 0.14 (1.62%)
PPL 82.30 Decreased By ▼ -1.00 (-1.2%)
PRL 24.10 Increased By ▲ 0.05 (0.21%)
PTC 9.11 Decreased By ▼ -0.04 (-0.44%)
SILK 1.33 Decreased By ▼ -0.03 (-2.21%)
SNGP 39.10 Decreased By ▼ -0.25 (-0.64%)
TRG 176.00 Increased By ▲ 5.00 (2.92%)
UNITY 30.75 Decreased By ▼ -0.50 (-1.6%)
WTL 1.55 Increased By ▲ 0.03 (1.97%)
BR100 4,795 Decreased By ▼ -29.74 (-0.62%)
BR30 24,960 Decreased By ▼ -99.54 (-0.4%)
KSE100 44,707 Decreased By ▼ -222.85 (-0.5%)
KSE30 18,276 Decreased By ▼ -98.7 (-0.54%)

Coronavirus
VERY HIGH
Pakistan Deaths
16,842
14424hr
Pakistan Cases
784,108
587024hr
Sindh
275,815
Punjab
282,469
Balochistan
21,365
Islamabad
72,150
KPK
110,875
World

Global COVID-19 prevention trial of hydroxychloroquine to resume

  • Global trial is part of search for way to prevent COVID-19.
  • COPCOV study was paused after results of treatment trial.
  • Trump hailed hydroxychloroquine as a game-changer.
30 Jun 2020

LONDON: A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.

The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known as the COPCOV trial after hydroxychloroquine was found in another British trial to have no benefit as a treatment for patients already infected with COVID-19, the disease caused by the new coronavirus.

The COPCOV study was paused pending review after the treatment trial results.

It is a randomised, placebo-controlled trial that is aiming to enrol 40,000 healthcare workers and other at-risk staff around the world, and is being led by the Oxford University's Mahidol Oxford Tropical Medicine Research Unit (MORU) in the Thai capital, Bangkok.

US President Donald Trump said in March hydroxychloroquine could be a game-changer and then said he was taking it himself, even after the US regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven.

The FDA later revoked emergency use authorisation for the drugs to treat COVID-19, after trials showed they were of no benefit as treatments.

But Oxford University's Professor Nicholas White, who is co-leading the COPCOV trial, said studies of the drugs as a potential preventative medicine had not yet given a conclusive answer.

"Hydroxychloroquine could still prevent infections, and this needs to be determined in a randomised controlled trial," he said in a statement. "The question whether (it) can prevent COVID-19 or not remains as pertinent as ever."

White's team said recruitment of British health workers would resume this week, and said plans were under way for new sites in Thailand and Southeast Asia, Africa and South America. Results are expected by the end of this year.

The death toll from COVID-19 surpassed half a million people on Sunday, according to a Reuters tally, with the number of cases reported globally now more than 10 million.